Bio Green Med Solution, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
BGMS$0.80-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(In $000s)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2025 | 2024 | |
| Net loss | $(81) | $(2,946) |
| Translation adjustment | 2,385 | 2,140 |
| Translation adjustment on deconsolidation of subsidiary | 886 | — |
| Unrealized foreign exchange loss on intercompany loans | (2,380) | (2,130) |
| Comprehensive loss | $810 | $(2,936) |
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(In $000s, except share amounts)
| Additional · Other · Total Stockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Paid-in · Comprehensive · Accumulated · Equity | ||||||||
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | (Deficit) | |
| Balances at December 31, 2023 | 454,537 | $— | 1,058,892 | $1 | $429,796 | $(908) | $(428,282) | $607 |
| Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering | — | — | 219,700 | — | (80) | — | — | (80) |
| Series B Preferred stock conversions | (119,000) | — | 39,667 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 203 | — | — | 203 |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | (2,130) | — | (2,130) |
| Translation adjustment | — | — | — | — | — | 2,140 | — | 2,140 |
| Loss for the period | — | — | — | — | — | — | (2,946) | (2,946) |
| Balances at March 31, 2024 | 335,537 | $— | 1,318,259 | $1 | $429,919 | $(898) | $(431,228) | $(2,206) |
| Balances at December 31, 2024 | 135,537 | $— | 8,859,133 | $9 | $438,202 | $(891) | $(439,494) | $(2,174) |
| Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses | — | — | — | — | (248) | — | — | (248) |
| Issue of Series C preferred stock in Securities Purchase Agreement | 1,000,000 | 1 | — | — | 999 | — | — | 1,000 |
| Series C Preferred stock conversions | (1,000,000) | (1) | 2,650,000 | 3 | (2) | — | — | — |
| Issue of Series D preferred stock in Securities Purchase Agreement | 2,100,000 | 2 | — | — | 1,892 | — | — | 1,894 |
| Series D Preferred stock conversions | (1,745,262) | (2) | 191,978,820 | 192 | (190) | — | — | — |
| Issue of Series D preferred stock in Securities Purchase Agreement | 1,000,000 | 1 | — | — | 999 | — | — | 1,000 |
| Warrant Exercise | — | — | 3,666,485 | — | — | — | — | — |
| Issue of common stock on Securities Purchase Agreement | — | — | 181,951 | — | — | — | — | — |
| Stock-based compensation | — | — | — | — | 1,666 | — | — | 1,666 |
| Deconsolidation of Subsidiary | — | — | — | — | — | 886 | (886) | — |
| Unrealized foreign exchange on intercompany loans | — | — | — | — | — | (2,380) | — | (2,380) |
| Translation adjustment | — | — | — | — | — | 2,385 | — | 2,385 |
| Loss for the period | — | — | — | — | — | — | (81) | (81) |
| Balances at March 31, 2025 | 1,490,275 | $1 | 207,336,389 | $204 | $443,318 | $— | $(440,461) | $3,062 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.